TLSI

$4.02

Post-MarketAs of Mar 17, 8:00 PM UTC

TriSalus Life Sciences, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$4.02
Potential Upside
5%
Whystock Fair Value$4.22
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in th...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$240.44M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.44
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.35

Recent News

Insider Monkey
Mar 12, 2026

Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On March 6, 2026, Canaccord analyst William Plovanic lowered the price target on TriSalus Life Sciences, Inc. (NASDAQ:TLSI) to $7 from $12 previously and maintained a Buy rating. William Plovanic said Q4 results came in line with the […]

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Moby
Mar 6, 2026

TriSalus Life Sciences, Inc. Q4 2025 Earnings Call Summary

Moby summary of TriSalus Life Sciences, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Mar 6, 2026

TriSalus Life Sciences Q4 Earnings Call Highlights

TriSalus Life Sciences (NASDAQ:TLSI) reported fourth-quarter and full-year 2025 results that management characterized as “strong,” driven by growth in its TriNav product suite and broader adoption of its Pressure-Enabled Drug Delivery (PEDD) platform beyond liver-directed procedures. Revenue growth

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 6, 2026

TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...

TriSalus Life Sciences Inc (TLSI) reports a 60% revenue increase and strategic growth plans, despite facing operational losses and delayed clinical data releases.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 5, 2026

TriSalus (TLSI) Q4 2025 Earnings Call Transcript

Need a quote from a Motley Fool analyst? Ms. Szela will provide an overview of the company's fourth quarter results and strategy for the balance of the year, and then David will review the financial results for the quarter in detail.

BEARISH
Negative press. News cycle fixated on risk factors or misses.